Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Invested Capital (2020 - 2025)

Keros Therapeutics (KROS) has disclosed Return on Invested Capital for 5 consecutive years, with 0.13% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Invested Capital rose 51.0% year-over-year to 0.13%, compared with a TTM value of 0.13% through Dec 2025, up 51.0%, and an annual FY2025 reading of 0.15%, up 61.0% over the prior year.
  • Return on Invested Capital was 0.13% for Q4 2025 at Keros Therapeutics, up from 0.06% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.13% in Q4 2025 and bottomed at 0.4% in Q3 2022.
  • Average Return on Invested Capital over 4 years is 0.19%, with a median of 0.24% recorded in 2021.
  • The sharpest move saw Return on Invested Capital plummeted -102bps in 2021, then surged 51bps in 2025.
  • Year by year, Return on Invested Capital stood at 0.25% in 2021, then tumbled by -57bps to 0.4% in 2022, then increased by 4bps to 0.38% in 2024, then soared by 133bps to 0.13% in 2025.
  • Business Quant data shows Return on Invested Capital for KROS at 0.13% in Q4 2025, 0.06% in Q3 2025, and 0.0% in Q2 2025.